1. Hemostatic efficacy of latest-generation fibrin sealant after hepatic resection: a randomized controlled clinical study
- Author
-
Jan Schmidt, Hüseyin Bektas, Ildiko Szabo, Silvio Nadalin, Marlies Sharkhawy, and Bettina Ploder
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Fibrin Tissue Adhesive ,Fibrin ,Hemostatics ,law.invention ,Aprotinin ,Randomized controlled trial ,law ,medicine ,Hepatectomy ,Humans ,Single-Blind Method ,Prospective Studies ,Prospective cohort study ,biology ,business.industry ,Sealant ,Liver Neoplasms ,Hemostasis, Surgical ,Surgery ,Hemostasis ,Anesthesia ,biology.protein ,business ,Abdominal surgery ,medicine.drug - Abstract
This randomized, controlled, single-blinded multicenter study evaluated the efficacy of latest-generation fibrin sealant containing synthetic aprotinin as fibrinolysis inhibitor as supportive treatment for hemostasis after elective partial hepatectomy. Adult subjects undergoing resection of at least one liver segment were assigned to treatment with fibrin sealant or manual compression with a surgical gauze swab if persistent oozing necessitated additional hemostatic measures after primary control of arterial and venous bleeding. The primary outcome measure was the proportion of subjects with intraoperative hemostasis at 4 min after start of randomized treatment application. Secondary efficacy outcome measures included intraoperative hemostasis at 6, 8, and 10 min, intra- and postoperative rebleedings, transfusion requirements, and drainage volume. Seventy subjects were randomized. Hemostasis at 4 min was achieved in 29/35 (82.9 %) fibrin sealant subjects compared with 13/35 (37.1 %) control subjects (p
- Published
- 2013